Calamos Wealth Management LLC Buys 10,616 Shares of Stryker Corporation $SYK

Calamos Wealth Management LLC increased its stake in shares of Stryker Corporation (NYSE:SYK) by 30.2% during the first quarter, HoldingsChannel.com reports. The fund owned 45,781 shares of the medical technology company’s stock after purchasing an additional 10,616 shares during the period. Calamos Wealth Management LLC’s holdings in Stryker were worth $15,043,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter worth approximately $26,000. Sankala Group LLC bought a new position in shares of Stryker in the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the fourth quarter worth $27,000. Finally, DJE Kapital AG acquired a new stake in shares of Stryker in the fourth quarter worth $28,000. 77.09% of the stock is owned by institutional investors.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the sale, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

SYK has been the topic of a number of research analyst reports. Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. Argus set a $370.00 price objective on Stryker in a research note on Thursday. Needham & Company LLC cut their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Citigroup decreased their target price on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Finally, Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $392.52.

Stryker Stock Performance

NYSE:SYK opened at $332.20 on Tuesday. The firm’s 50-day moving average is $310.47 and its 200-day moving average is $337.68. The company has a market cap of $127.35 billion, a price-to-earnings ratio of 38.45, a PEG ratio of 2.11 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.